JeanMarie Guenot Is Saving Lives With Her Research

Jeanmarie Guenot is a Ph.D. recipient with decades of experience in the biotech industry. She has had a colorful career in different private companies including venture capital groups. She is currently dedicated as the CEO of Amphivena Therapeutics, which develops some of the most game-changing drugs on the market.

Prior to her involvement with Amphivena, Jeanmarie Guenot was running her company SKS Ocular. The company successfully released treatments for glaucoma, macular degeneration and ocular inflammation. She had also done advising for Hoffmann-La Roche and PDL BioPharma. Her prior position at Hoffmann-La Roche was to develop drugs for metabolic diseases.

Jeanmarie Guenot’s first job was with Atlas Venture. At her position, she managed for funding and formation of life science industries. Jeanmarie Guenot earning her Ph.D. from the University of California prior to her career.

Amphivena is heavily invested in developing antibody therapies. They hope to treat types of blood cancers that are currently neglected in the medical market on guenotllc.com. They had recently developed Tandem antibiotics to treat acute myeloid leukemia. The company is partnered with Janssen Biotech and Affimed Therapeutics AG.

Not only is Amphivena responsible for life-saving research, but they also employ a female dominant staff. The entire executive team consists of well-educated females.

Also within the company is Dr. Lori Kunkel. Her career has consisted of executive positions for companies involved with commercializing oncologic/immunologic therapies. She had ben actively employed with venture capital groups located in the Boston and Bay area.

Judith A. Fox is the Vice President of Amphivena. She is primarily responsible for the research and development part of the company. With her previous employment at Sunesis Pharmaceuticals, she developed groundbreaking research with acute myeloid leukemia. She was also previously a director of the Translational Sciences department at Chiron Corporation.

Managing Director Jennifer Sims holds quite and important position for the company as well. She has over 25 years of corporate experience in the molecule and biological drug development world. Her career has also had a primary focus on biological products. She is an expert at administering clinical trials and marketing of relevant pharmaceutical products.

Read more: Collaboration to Advance T-Cell Engagement Therapies

Leave a Reply